BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Leukemia
,
Pancreas
,
Metabolism of nitric oxide
,
Rosiglitazone
,
rs2300478
,
CYP51
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
vx680
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
CPVL
XIST
TNFAIP3
HAL
COL11A1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
regulation of nitrogen compound metabolic process
organic cyclic compound binding
heterocyclic compound binding
cytosol
nucleoplasm
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Lung cancer KRAS-mutant A549 cells treated with aurora kinase inhibitors VX680, AZD1152, and MLN8237
L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Aurora kinase inhibitor VX-680 enhances sensitivity of esophageal squamous cell carcinoma cells to c…
Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis…
Interaction of novel Aurora kinase inhibitor MK-0457 with human serum albumin: Insights into the dyn…
VX-680 induces p53-mediated apoptosis in human cholangiocarcinoma cells.
The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for vx680
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ